首页 > 最新文献

Journal of Gene Medicine最新文献

英文 中文
PDCL3 as a prognostic factor and associated with the VEGF signaling pathway in glioma PDCL3是胶质瘤的预后因子,与血管内皮生长因子信号通路相关。
IF 3.2 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Pub Date : 2024-08-06 DOI: 10.1002/jgm.3724
Bo Yang, Guangwei Zheng, Feng Lu

Background

New targeted drugs about angiogenesis could develop the treatment of glioma. We aimed to explore the role of phosducin like 3 (PDCL3) in angiogenesis of glioma.

Materials and Methods

RNA sequencing data and matched clinical data were downloaded from The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) databases. To screen for the reliable genes with the filtering analyses, survival, multivariate Cox, receiver operating characteristic (ROC) curve filtration, and clinical correlation analyses were performed. The PDCL3 gene was validated by immunohistochemistry as a reliable gene for further analysis. Then we used the combined data of TCGA and Genotype-Tissue Expression from UCSC to detect the differential gene expression of PDCL3. Related signal pathways in glioma were explored by the gene set enrichment analysis and co-expression analysis. Lastly, we performed in vitro experiments to verify the gene functions and related mechanisms.

Results

The three filtering analyses and immunostaining indicated that the expression of PDCL3 in glioma tissues was higher than the normal tissues. Gene function analysis showed that PDCL3 activated the vascular endothelial growth factor (VEGF) signal pathway, and its mechanism was related to pathways in cancer, like NOD like receptor signaling pathway, the RIG-I like receptor signaling pathway and the P53 signaling pathway by MAPK/AKT in gliomas. This suggested that the proliferation, migration and invasion of glioma cells might be inhibited by the downregulation of PDCL3 in vitro, which may be related to the activation of VEGF signaling pathway.

Conclusion

We demonstrated that PDCL3 could function as an independent adverse prognostic marker in glioma. Its pro-oncogenic mechanism may be related to the VEGF signaling pathway.

背景:有关血管生成的新靶向药物可促进胶质瘤的治疗。我们的目的是探讨类磷脂蛋白3(PDCL3)在胶质瘤血管生成中的作用:从癌症基因组图谱(The Cancer Genome Atlas,TCGA)和中国胶质瘤基因组图谱(Chinese Glioma Genome Atlas,CGGA)数据库下载RNA测序数据和匹配的临床数据。为筛选出可靠的基因,进行了生存分析、多变量 Cox 分析、接收者操作特征曲线(ROC)筛选分析和临床相关性分析。经免疫组化验证,PDCL3基因是进一步分析的可靠基因。然后,我们利用 TCGA 和 UCSC 的基因型-组织表达联合数据检测了 PDCL3 的差异基因表达。通过基因组富集分析和共表达分析,我们探索了胶质瘤中的相关信号通路。最后,我们进行了体外实验来验证基因的功能和相关机制:结果:三种筛选分析和免疫染色表明,PDCL3在胶质瘤组织中的表达高于正常组织。基因功能分析表明,PDCL3能激活血管内皮生长因子(VEGF)信号通路,其机制与肿瘤中的通路有关,如胶质瘤中的NOD样受体信号通路、RIG-I样受体信号通路和MAPK/AKT的P53信号通路。这表明,体外下调PDCL3可抑制胶质瘤细胞的增殖、迁移和侵袭,这可能与血管内皮生长因子信号通路的激活有关:结论:我们的研究表明,PDCL3可作为胶质瘤独立的不良预后标志物。结论:我们的研究表明,PDCL3可作为胶质瘤的独立不良预后标志物,其促癌机制可能与血管内皮生长因子信号通路有关。
{"title":"PDCL3 as a prognostic factor and associated with the VEGF signaling pathway in glioma","authors":"Bo Yang,&nbsp;Guangwei Zheng,&nbsp;Feng Lu","doi":"10.1002/jgm.3724","DOIUrl":"10.1002/jgm.3724","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>New targeted drugs about angiogenesis could develop the treatment of glioma. We aimed to explore the role of phosducin like 3 (PDCL3) in angiogenesis of glioma.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>RNA sequencing data and matched clinical data were downloaded from The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) databases. To screen for the reliable genes with the filtering analyses, survival, multivariate Cox, receiver operating characteristic (ROC) curve filtration, and clinical correlation analyses were performed. The PDCL3 gene was validated by immunohistochemistry as a reliable gene for further analysis. Then we used the combined data of TCGA and Genotype-Tissue Expression from UCSC to detect the differential gene expression of PDCL3. Related signal pathways in glioma were explored by the gene set enrichment analysis and co-expression analysis. Lastly, we performed <i>in vitro</i> experiments to verify the gene functions and related mechanisms.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The three filtering analyses and immunostaining indicated that the expression of PDCL3 in glioma tissues was higher than the normal tissues. Gene function analysis showed that PDCL3 activated the vascular endothelial growth factor (VEGF) signal pathway, and its mechanism was related to pathways in cancer, like NOD like receptor signaling pathway, the RIG-I like receptor signaling pathway and the P53 signaling pathway by MAPK/AKT in gliomas. This suggested that the proliferation, migration and invasion of glioma cells might be inhibited by the downregulation of PDCL3 <i>in vitro</i>, which may be related to the activation of VEGF signaling pathway.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>We demonstrated that PDCL3 could function as an independent adverse prognostic marker in glioma. Its pro-oncogenic mechanism may be related to the VEGF signaling pathway.</p>\u0000 </section>\u0000 </div>","PeriodicalId":56122,"journal":{"name":"Journal of Gene Medicine","volume":"26 8","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141899017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety of intravitreally delivered AAV2 vector-mediated multi-characteristic opsin genetic construct in wild type beagle dogs 在野生型小猎犬体内静脉注射 AAV2 向量介导的多特征蛋白基因构建物的安全性。
IF 3.2 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Pub Date : 2024-07-23 DOI: 10.1002/jgm.3720
Samarendra Mohanty, Subrata Batabyal, Ananta Ayyagari, Najam A. Sharif

Background

A novel adeno-associated virus 2 (AAV2)-carried multi-characteristic opsin (MCO) (MCO-010) is undergoing several clinical trials as a novel therapeutic modality for the treatment of degenerative retinal diseases including retinitis pigmentosa and Stargardt disease. The present study aimed to determine the ocular and systemic safety of MCO-010 and the AAV2 vehicle in adult Beagle dogs following intravitreal (IVT) injection.

Methods

The current safety/toxicology studies spanning 13 weeks described here utilized well-documented techniques to assess the effects of IVT injection of MCO-010 up to 2.2 × 1011 genome copies (gc) per eye, or the AAV2 capsid (vehicle control) on gross behavioral and immunogenic changes, alterations in body weights, blood biochemistry, hematology, blood coagulation, gross necropsy lesions, organ weight changes and histopathology in the dogs (n = 4 per group; two males and two females per group). Immunohistochemical and functional electroretinogram studies were also conducted to determine MCO expression in the retina and determine any retinal toxicity associated with MCO-010.

Results

There were no significant deleterious effects of the MCO-010 (or the AAV2 at the tested doses) on any of the examined parameters, including the absence of any severe ocular or systemic adverse events. However, as expected, inflammation after IVT delivery of AAV2 and MCO-010 was observed in the conjunctivae of all groups of animals, although this self-resolved within 1 week post-injection. Quantitative immunohistochemical analyses of MCO-010-associated mCherry revealed successful delivery of the gene therapy within the inner retina.

Conclusions

In summary, MCO-010 demonstrated a favorable safety profile when administered to the eyes of adult Beagle dogs of both sexes at dose levels up to 2.2 × 1011 gc per eye, with no adverse effects observed. This dose was identified as the No Observed Adverse Effect Level (i.e. NOAEL) and guided selection of safe doses for human clinical trials.

背景:一种新型腺相关病毒2(AAV2)携带的多特性视蛋白(MCO)(MCO-010)正在进行多项临床试验,它是治疗视网膜变性疾病(包括视网膜色素变性和Stargardt病)的一种新型治疗方法。本研究旨在确定 MCO-010 和 AAV2 载体在成年比格犬体内静脉注射后的眼部和全身安全性:本文所述的安全性/毒理学研究时间跨度为 13 周,采用的是有据可查的技术来评估 IVT 注射 MCO-010 的影响,最高剂量为 2.2 × 1011 个基因组拷贝 (gc) 或 AAV2 包膜(载体对照)对狗(每组 4 只;每组 2 只雌雄狗)行为和免疫原性变化、体重变化、血液生化、血液学、血液凝固、尸检病变、器官重量变化和组织病理学的影响。还进行了免疫组化和功能性视网膜电图研究,以确定视网膜中 MCO 的表达,并确定 MCO-010 是否对视网膜产生毒性:结果:MCO-010(或测试剂量的AAV2)对任何检查参数都没有明显的有害影响,包括没有出现任何严重的眼部或全身不良反应。不过,正如预期的那样,所有组别动物的结膜在静脉注射 AAV2 和 MCO-010 后都出现了炎症,不过这种炎症在注射后一周内自行消退。对 MCO-010 相关 mCherry 的定量免疫组化分析表明,基因疗法成功地在视网膜内层传递:总之,MCO-010在对成年比格犬(雌雄均可)的眼睛进行注射时表现出良好的安全性,每只眼睛的注射剂量最高可达2.2 × 1011 gc,且未观察到任何不良反应。该剂量被确定为未观察到不良反应水平(即 NOAEL),为人体临床试验选择安全剂量提供了指导。
{"title":"Safety of intravitreally delivered AAV2 vector-mediated multi-characteristic opsin genetic construct in wild type beagle dogs","authors":"Samarendra Mohanty,&nbsp;Subrata Batabyal,&nbsp;Ananta Ayyagari,&nbsp;Najam A. Sharif","doi":"10.1002/jgm.3720","DOIUrl":"10.1002/jgm.3720","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>A novel adeno-associated virus 2 (AAV2)-carried multi-characteristic opsin (MCO) (MCO-010) is undergoing several clinical trials as a novel therapeutic modality for the treatment of degenerative retinal diseases including retinitis pigmentosa and Stargardt disease. The present study aimed to determine the ocular and systemic safety of MCO-010 and the AAV2 vehicle in adult Beagle dogs following intravitreal (IVT) injection.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The current safety/toxicology studies spanning 13 weeks described here utilized well-documented techniques to assess the effects of IVT injection of MCO-010 up to 2.2 × 10<sup>11</sup> genome copies (gc) per eye, or the AAV2 capsid (vehicle control) on gross behavioral and immunogenic changes, alterations in body weights, blood biochemistry, hematology, blood coagulation, gross necropsy lesions, organ weight changes and histopathology in the dogs (n = 4 per group; two males and two females per group). Immunohistochemical and functional electroretinogram studies were also conducted to determine MCO expression in the retina and determine any retinal toxicity associated with MCO-010.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>There were no significant deleterious effects of the MCO-010 (or the AAV2 at the tested doses) on any of the examined parameters, including the absence of any severe ocular or systemic adverse events. However, as expected, inflammation after IVT delivery of AAV2 and MCO-010 was observed in the conjunctivae of all groups of animals, although this self-resolved within 1 week post-injection. Quantitative immunohistochemical analyses of MCO-010-associated mCherry revealed successful delivery of the gene therapy within the inner retina.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In summary, MCO-010 demonstrated a favorable safety profile when administered to the eyes of adult Beagle dogs of both sexes at dose levels up to 2.2 × 10<sup>11</sup> gc per eye, with no adverse effects observed. This dose was identified as the No Observed Adverse Effect Level (i.e. NOAEL) and guided selection of safe doses for human clinical trials.</p>\u0000 </section>\u0000 </div>","PeriodicalId":56122,"journal":{"name":"Journal of Gene Medicine","volume":"26 7","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141749834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Icariin attenuates asthmatic airway inflammation via modulating alveolar macrophage activation based on network pharmacology and in vivo experiments 基于网络药理学和体内实验,淫羊藿苷通过调节肺泡巨噬细胞活化减轻哮喘气道炎症。
IF 3.2 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Pub Date : 2024-07-09 DOI: 10.1002/jgm.3718
Xiaofei Zhu, Bin Wang, Hang Yu, Congcong Li, Yuhang Zhao, Yuanyuan Zhong, Weifeng Tang, Yaolong Zhou, Xi Huang, Huahe Zhu, Yueren Wu, Kai Yang, Ying Wei, Zhen Gao, Jingcheng Dong

Background

Icariin (ICA) inhibits inflammatory response in various diseases, but the mechanism underlying ICA treating airway inflammation in asthma needs further understood. We aimed to predict and validate the potential targets of ICA against asthma-associated airway inflammation using network pharmacology and experiments.

Methods

The ovalbumin-induced asthma-associated airway inflammation mice model was established. The effects of ICA were evaluated by behavioral, airway hyperresponsiveness, lung pathological changes, inflammatory cell and cytokines counts. Next, the corresponding targets of ICA were mined via the SEA, CTD, HERB, PharmMapper, Symmap database and the literature. Pubmed-Gene and GeneCards databases were used to screen asthma and airway inflammation-related targets. The overlapping targets were used to build an interaction network, analyze gene ontology and enrich pathways. Subsequently, flow cytometry, quantitative real-time PCR and western blotting were employed for validation.

Results

ICA alleviated the airway inflammation of asthma; 402 targets of ICA, 5136 targets of asthma and 4531 targets of airway inflammation were screened; 216 overlapping targets were matched and predicted ICA possesses the potential to modulate asthmatic airway inflammation by macrophage activation/polarization. Additionally, ICA decreased M1 but elevated M2. Potential targets that were disrupted by asthma inflammation were restored by ICA treatment.

Conclusions

ICA alleviates airway inflammation in asthma by inhibiting the M1 polarization of alveolar macrophages, which is related to metabolic reprogramming. Jun, Jak2, Syk, Tnf, Aldh2, Aldh9a1, Nos1, Nos2 and Nos3 represent potential targets of therapeutic intervention. The present study enhances understanding of the anti-airway inflammation effects of ICA, especially in asthma.

背景:淫羊藿苷(ICA)可抑制多种疾病的炎症反应,但ICA治疗哮喘气道炎症的机制有待进一步了解。我们的目的是利用网络药理学和实验预测并验证淫羊藿苷治疗哮喘相关气道炎症的潜在靶点:方法:建立卵清蛋白诱导的哮喘相关气道炎症小鼠模型。方法:建立卵清蛋白诱导的哮喘相关气道炎症小鼠模型,通过行为学、气道高反应性、肺部病理变化、炎症细胞和细胞因子计数评估 ICA 的作用。然后,通过 SEA、CTD、HERB、PharmMapper、Symmap 数据库和文献挖掘 ICA 的相应靶点。Pubmed-Gene 和 GeneCards 数据库用于筛选哮喘和气道炎症相关靶点。重叠的靶点被用于构建相互作用网络、分析基因本体和丰富通路。随后,采用流式细胞术、实时定量 PCR 和 Western 印迹技术进行验证:结果:ICA可减轻哮喘的气道炎症;筛选出ICA的402个靶点、哮喘的5136个靶点和气道炎症的4531个靶点;216个重叠靶点被匹配并预测ICA具有通过巨噬细胞活化/极化来调节哮喘气道炎症的潜力。此外,ICA 降低了 M1,但升高了 M2。哮喘炎症破坏的潜在靶点在ICA治疗后得到恢复:ICA通过抑制肺泡巨噬细胞的M1极化缓解了哮喘的气道炎症,而M1极化与代谢重编程有关。Jun、Jak2、Syk、Tnf、Aldh2、Aldh9a1、Nos1、Nos2和Nos3是治疗干预的潜在靶点。本研究加深了人们对 ICA 抗气道炎症作用的了解,尤其是在哮喘中。
{"title":"Icariin attenuates asthmatic airway inflammation via modulating alveolar macrophage activation based on network pharmacology and in vivo experiments","authors":"Xiaofei Zhu,&nbsp;Bin Wang,&nbsp;Hang Yu,&nbsp;Congcong Li,&nbsp;Yuhang Zhao,&nbsp;Yuanyuan Zhong,&nbsp;Weifeng Tang,&nbsp;Yaolong Zhou,&nbsp;Xi Huang,&nbsp;Huahe Zhu,&nbsp;Yueren Wu,&nbsp;Kai Yang,&nbsp;Ying Wei,&nbsp;Zhen Gao,&nbsp;Jingcheng Dong","doi":"10.1002/jgm.3718","DOIUrl":"10.1002/jgm.3718","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Icariin (ICA) inhibits inflammatory response in various diseases, but the mechanism underlying ICA treating airway inflammation in asthma needs further understood. We aimed to predict and validate the potential targets of ICA against asthma-associated airway inflammation using network pharmacology and experiments.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The ovalbumin-induced asthma-associated airway inflammation mice model was established. The effects of ICA were evaluated by behavioral, airway hyperresponsiveness, lung pathological changes, inflammatory cell and cytokines counts. Next, the corresponding targets of ICA were mined via the SEA, CTD, HERB, PharmMapper, Symmap database and the literature. Pubmed-Gene and GeneCards databases were used to screen asthma and airway inflammation-related targets. The overlapping targets were used to build an interaction network, analyze gene ontology and enrich pathways. Subsequently, flow cytometry, quantitative real-time PCR and western blotting were employed for validation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>ICA alleviated the airway inflammation of asthma; 402 targets of ICA, 5136 targets of asthma and 4531 targets of airway inflammation were screened; 216 overlapping targets were matched and predicted ICA possesses the potential to modulate asthmatic airway inflammation by macrophage activation/polarization. Additionally, ICA decreased M1 but elevated M2. Potential targets that were disrupted by asthma inflammation were restored by ICA treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>ICA alleviates airway inflammation in asthma by inhibiting the M1 polarization of alveolar macrophages, which is related to metabolic reprogramming. <i>Jun</i>, <i>Jak2</i>, <i>Syk</i>, <i>Tnf</i>, <i>Aldh2</i>, <i>Aldh9a1</i>, <i>Nos1</i>, <i>Nos2</i> and <i>Nos3</i> represent potential targets of therapeutic intervention. The present study enhances understanding of the anti-airway inflammation effects of ICA, especially in asthma.</p>\u0000 </section>\u0000 </div>","PeriodicalId":56122,"journal":{"name":"Journal of Gene Medicine","volume":"26 7","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141560386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification and characterization of RAC1-related immune and prognostic subtypes of hepatocellular carcinoma 肝细胞癌 RAC1 相关免疫亚型和预后亚型的鉴定与特征描述。
IF 3.2 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Pub Date : 2024-07-09 DOI: 10.1002/jgm.3719
Wei Wang, Hui Xia, Pei Feng, Bin Dai

Background

Hepatocellular carcinoma (HCC) is a malignant tumor with significant variability in prognosis among patients. Ras-related C3 botulinum toxin substrate 1 (RAC1) is a key focus in the area of cancer research. However, the molecular mechanisms of RAC1 in HCC remain incompletely elucidated.

Materials and methods

In this study, bioinformatics analysis was used, and public databases were used to obtain information about HCC cases. The samples were categorized into two groups of high and low expression based on the expression level of RAC1 gene. The limma package was used to calculate the differentially expressed genes between the two groups, and univariate Cox regression analysis was used to screen the prognostic related factors. Consensus clustering analysis was performed using the ConsensusClusterPlus package to identify molecular subtypes of HCC patients. Immune cell infiltration and ESTIMATE scores were assessed using the single sample gene set enrichment analysis and ESTIMATE algorithms. The sensitivity of different isoforms to chemotherapeutic agents was predicted by the oncoPredict package. Finally, we also performed cell function experiments to validate the biological role of RAC1 in vitro. Initially, we classified patients into high and low expression groups based on RAC1 gene expression levels and identified 195 up-regulated genes and 107 down-regulated genes. Through univariate Cox regression analysis, we screened out 169 prognosis-related factors. Furthermore, HCC patients were categorized into two subtypes. Subsequently, Kaplan–Meier survival curves showed that there was a significant difference in prognosis between the two molecular subtypes. Further analysis indicated substantial differences in gene expression levels and TIDE scores between two molecular subtypes. Moreover, these two subtypes exhibited varying sensitivity to chemotherapy drugs, as evidenced by differences in IC50 values. In addition, we found that the silence of RAC1 could effectively inhibit the migration and invasion of HCC cells in vitro.

Conclusion

This study sheds light on the molecular intricacies of RAC1 in HCC and identifies patient populations that may benefit from immunotherapeutic interventions, with potential implications for tailored treatment strategies.

背景:肝细胞癌(HCC)是一种恶性肿瘤,不同患者的预后差异很大。Ras 相关 C3 肉毒毒素底物 1(RAC1)是癌症研究领域的一个重点。然而,RAC1在HCC中的分子机制仍未完全阐明:本研究采用生物信息学分析方法,并利用公共数据库获取有关 HCC 病例的信息。根据 RAC1 基因的表达水平,将样本分为高表达和低表达两组。使用 limma 软件包计算两组间差异表达的基因,并使用单变量 Cox 回归分析筛选预后相关因素。使用ConsensusClusterPlus软件包进行共识聚类分析,以确定HCC患者的分子亚型。利用单样本基因组富集分析和ESTIMATE算法评估了免疫细胞浸润和ESTIMATE评分。oncoPredict软件包预测了不同异构体对化疗药物的敏感性。最后,我们还进行了细胞功能实验,以验证 RAC1 在体外的生物学作用。最初,我们根据 RAC1 基因的表达水平将患者分为高表达组和低表达组,并确定了 195 个上调基因和 107 个下调基因。通过单变量 Cox 回归分析,我们筛选出了 169 个与预后相关的因素。此外,我们还将 HCC 患者分为两个亚型。随后,Kaplan-Meier 生存曲线显示,两种分子亚型的预后存在显著差异。进一步的分析表明,两种分子亚型的基因表达水平和 TIDE 评分存在很大差异。此外,这两种亚型对化疗药物的敏感性也不尽相同,IC50 值的差异就证明了这一点。此外,我们还发现沉默 RAC1 能有效抑制 HCC 细胞在体外的迁移和侵袭:本研究揭示了 RAC1 在 HCC 中的分子复杂性,并确定了可能从免疫治疗干预中获益的患者群体,这对定制治疗策略具有潜在的意义。
{"title":"Identification and characterization of RAC1-related immune and prognostic subtypes of hepatocellular carcinoma","authors":"Wei Wang,&nbsp;Hui Xia,&nbsp;Pei Feng,&nbsp;Bin Dai","doi":"10.1002/jgm.3719","DOIUrl":"10.1002/jgm.3719","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Hepatocellular carcinoma (HCC) is a malignant tumor with significant variability in prognosis among patients. Ras-related C3 botulinum toxin substrate 1 (RAC1) is a key focus in the area of cancer research. However, the molecular mechanisms of RAC1 in HCC remain incompletely elucidated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and methods</h3>\u0000 \u0000 <p>In this study, bioinformatics analysis was used, and public databases were used to obtain information about HCC cases. The samples were categorized into two groups of high and low expression based on the expression level of RAC1 gene. The limma package was used to calculate the differentially expressed genes between the two groups, and univariate Cox regression analysis was used to screen the prognostic related factors. Consensus clustering analysis was performed using the ConsensusClusterPlus package to identify molecular subtypes of HCC patients. Immune cell infiltration and ESTIMATE scores were assessed using the single sample gene set enrichment analysis and ESTIMATE algorithms. The sensitivity of different isoforms to chemotherapeutic agents was predicted by the oncoPredict package. Finally, we also performed cell function experiments to validate the biological role of RAC1 <i>in vitro</i>. Initially, we classified patients into high and low expression groups based on RAC1 gene expression levels and identified 195 up-regulated genes and 107 down-regulated genes. Through univariate Cox regression analysis, we screened out 169 prognosis-related factors. Furthermore, HCC patients were categorized into two subtypes. Subsequently, Kaplan–Meier survival curves showed that there was a significant difference in prognosis between the two molecular subtypes. Further analysis indicated substantial differences in gene expression levels and TIDE scores between two molecular subtypes. Moreover, these two subtypes exhibited varying sensitivity to chemotherapy drugs, as evidenced by differences in IC<sub>50</sub> values. In addition, we found that the silence of RAC1 could effectively inhibit the migration and invasion of HCC cells <i>in vitro</i>.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study sheds light on the molecular intricacies of RAC1 in HCC and identifies patient populations that may benefit from immunotherapeutic interventions, with potential implications for tailored treatment strategies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":56122,"journal":{"name":"Journal of Gene Medicine","volume":"26 7","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141560387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hematopoietic stem cell gene therapy for the treatment of SYNGAP1-related non-specific intellectual disability 用于治疗与 SYNGAP1 相关的非特异性智力障碍的造血干细胞基因疗法。
IF 3.2 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Pub Date : 2024-07-05 DOI: 10.1002/jgm.3717
Joseph S. Anderson, Alyse L. Lodigiani, Camilla M. Barbaduomo, Julie R. Beegle

Background

Synaptic Ras GTPase activating protein 1 (SYNGAP1)-related non-specific intellectual disability is a neurodevelopmental disorder caused by an insufficient level of SynGAP1 resulting in a dysfunction of neuronal synapses and presenting with a wide array of clinical phenotypes. Hematopoietic stem cell gene therapy has the potential to deliver therapeutic levels of functional SynGAP1 to affected neurons upon transduction of hematopoietic stem and progenitor cells with a lentiviral vector.

Methods

As a novel approach toward the treatment of SYNGAP1, we have generated a lentiviral vector expressing a modified form of SynGAP1 for transduction of human CD34+ hematopoietic stem and progenitor cells. The gene-modified cells were then transplanted into adult immunodeficient SYNGAP1+/− heterozygous mice and evaluated for improvement of SYNGAP1-related clinical phenotypes. Expression of SynGAP1 was also evaluated in the brain tissue of transplanted mice.

Results

In our proof-of-concept study, we have demonstrated significant improvement of SYNGAP1-related phenotypes including an improvement in motor abilities observed in mice transplanted with the vector transduced cells because they displayed decreased hyperactivity in an open field assay and an increased latency to fall in a rotarod assay. An increased level of SynGAP1 was also detected in the brains of these mice.

Conclusions

These early-stage results highlight the potential of this stem cell gene therapy approach as a treatment strategy for SYNGAP1.

背景:突触Ras GTP酶活化蛋白1 (SYNGAP1)相关非特异性智力障碍是一种神经发育障碍,由SynGAP1水平不足导致神经元突触功能障碍引起,表现出多种临床表型。造血干细胞基因疗法有可能通过慢病毒载体转导造血干细胞和祖细胞,为受影响的神经元提供治疗水平的功能性SynGAP1:作为治疗SYNGAP1的一种新方法,我们生成了一种表达SynGAP1修饰形式的慢病毒载体,用于转导人类CD34+造血干细胞和祖细胞。然后将基因修饰过的细胞移植到成年免疫缺陷SYNGAP1+/-杂合小鼠体内,并评估SYNGAP1相关临床表型的改善情况。同时还评估了移植小鼠脑组织中SynGAP1的表达情况:在我们的概念验证研究中,我们证明了 SYNGAP1 相关表型的显著改善,包括在移植了载体转导细胞的小鼠身上观察到的运动能力的改善,因为它们在开放场试验中表现出的过度活跃性降低了,在转体试验中的跌倒潜伏期增加了。在这些小鼠的大脑中还检测到了 SynGAP1 水平的升高:这些早期结果凸显了干细胞基因治疗方法作为SYNGAP1治疗策略的潜力。
{"title":"Hematopoietic stem cell gene therapy for the treatment of SYNGAP1-related non-specific intellectual disability","authors":"Joseph S. Anderson,&nbsp;Alyse L. Lodigiani,&nbsp;Camilla M. Barbaduomo,&nbsp;Julie R. Beegle","doi":"10.1002/jgm.3717","DOIUrl":"10.1002/jgm.3717","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Synaptic Ras GTPase activating protein 1 (SYNGAP1)-related non-specific intellectual disability is a neurodevelopmental disorder caused by an insufficient level of SynGAP1 resulting in a dysfunction of neuronal synapses and presenting with a wide array of clinical phenotypes. Hematopoietic stem cell gene therapy has the potential to deliver therapeutic levels of functional SynGAP1 to affected neurons upon transduction of hematopoietic stem and progenitor cells with a lentiviral vector.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>As a novel approach toward the treatment of SYNGAP1, we have generated a lentiviral vector expressing a modified form of SynGAP1 for transduction of human CD34+ hematopoietic stem and progenitor cells. The gene-modified cells were then transplanted into adult immunodeficient SYNGAP1+/− heterozygous mice and evaluated for improvement of SYNGAP1-related clinical phenotypes. Expression of SynGAP1 was also evaluated in the brain tissue of transplanted mice.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In our proof-of-concept study, we have demonstrated significant improvement of SYNGAP1-related phenotypes including an improvement in motor abilities observed in mice transplanted with the vector transduced cells because they displayed decreased hyperactivity in an open field assay and an increased latency to fall in a rotarod assay. An increased level of SynGAP1 was also detected in the brains of these mice.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>These early-stage results highlight the potential of this stem cell gene therapy approach as a treatment strategy for SYNGAP1.</p>\u0000 </section>\u0000 </div>","PeriodicalId":56122,"journal":{"name":"Journal of Gene Medicine","volume":"26 7","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jgm.3717","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141536110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Icariside II in NSCLC and COVID-19: Network pharmacology and molecular docking study 淫羊藿苷 II 在 NSCLC 和 COVID-19 中的作用:网络药理学和分子对接研究
IF 3.2 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Pub Date : 2024-07-05 DOI: 10.1002/jgm.3710
Qing Kong, Huahe Zhu, Jingcheng Dong, Baojun Liu

Background

Patients with non-small cell lung cancer (NSCLC) are susceptible to coronavirus disease-2019 (COVID-19), but current treatments are limited. Icariside II (IS), a flavonoid compound derived from the plant epimedin, showed anti-cancer,anti-inflammation and immunoregulation effects. The present study aimed to evaluate the possible effect and underlying mechanisms of IS on NSCLC patients with COVID-19 (NSCLC/COVID-19).

Methods

NSCLC/COVID-19 targets were defined as the common targets of NSCLC (collected from The Cancer Genome Atlas database) and COVID-19 targets (collected from disease database of Genecards, OMIM, and NCBI). The correlations of NSCLC/COVID-19 targets and survival rates in patients with NSCLC were analyzed using the survival R package. Prognostic analyses were performed using univariate and multivariate Cox proportional hazards regression models. Furthermore, the targets in IS treatment of NSCLC/COVID-19 were defined as the overlapping targets of IS (predicted from drug database of TMSCP, HERBs, SwissTarget Prediction) and NSCLC/COVID-19 targets. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analysis of these treatment targets were performed aiming to understand the biological process, cellular component, molecular function and signaling pathway. The hub targets were analyzed by a protein–protein interaction network and the binding capacity with IS was characterized by molecular docking.

Results

The hub targets for IS in the treatment of NSCLC/COVID-19 includes F2, SELE, MMP1, MMP2, AGTR1 and AGTR2, and the molecular docking results showed that the above target proteins had a good binding degree to IS. Network pharmacology showed that IS might affect the leucocytes migration, inflammation response and active oxygen species metabolic process, as well as regulate the interleukin-17, tumor necrosus factor and hypoxia-inducible factor-1 signaling pathway in NSCLC/COVID-19.

Conclusions

IS may enhance the therapeutic efficacy of current clinical anti-inflammatory and anti-cancer therapy to benefit patients with NSCLC combined with COVID-19.

背景:非小细胞肺癌(NSCLC)患者易感染冠状病毒病-2019(COVID-19),但目前的治疗方法有限。淫羊藿苷 II(IS)是从植物淫羊藿中提取的一种黄酮类化合物,具有抗癌、抗炎和免疫调节作用。本研究旨在评估IS对COVID-19(NSCLC/COVID-19)NSCLC患者可能产生的影响及其潜在机制:方法:NSCLC/COVID-19靶点定义为NSCLC常见靶点(从癌症基因组图谱数据库中收集)和COVID-19靶点(从Genecards、OMIM和NCBI的疾病数据库中收集)。使用生存 R 软件包分析了 NSCLC/COVID-19 靶点与 NSCLC 患者生存率的相关性。使用单变量和多变量考克斯比例危险回归模型进行了预后分析。此外,IS治疗NSCLC/COVID-19的靶点被定义为IS的重叠靶点(通过TMSCP、HERBs、SwissTarget Prediction药物数据库预测)和NSCLC/COVID-19靶点。对这些治疗靶点进行了基因本体和京都基因组百科全书的富集分析,旨在了解其生物学过程、细胞成分、分子功能和信号通路。通过蛋白质-蛋白质相互作用网络分析了这些中心靶标,并通过分子对接鉴定了它们与IS的结合能力:结果:IS治疗NSCLC/COVID-19的中心靶点包括F2、SELE、MMP1、MMP2、AGTR1和AGTR2。网络药理学研究表明,IS可影响NSCLC/COVID-19的白细胞迁移、炎症反应和活性氧代谢过程,并调控白细胞介素-17、肿瘤坏死因子和缺氧诱导因子-1的信号通路:IS可提高目前临床抗炎和抗癌疗法的疗效,使NSCLC/COVID-19患者受益。
{"title":"Icariside II in NSCLC and COVID-19: Network pharmacology and molecular docking study","authors":"Qing Kong,&nbsp;Huahe Zhu,&nbsp;Jingcheng Dong,&nbsp;Baojun Liu","doi":"10.1002/jgm.3710","DOIUrl":"10.1002/jgm.3710","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Patients with non-small cell lung cancer (NSCLC) are susceptible to coronavirus disease-2019 (COVID-19), but current treatments are limited. Icariside II (IS), a flavonoid compound derived from the plant epimedin, showed anti-cancer,anti-inflammation and immunoregulation effects. The present study aimed to evaluate the possible effect and underlying mechanisms of IS on NSCLC patients with COVID-19 (NSCLC/COVID-19).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>NSCLC/COVID-19 targets were defined as the common targets of NSCLC (collected from The Cancer Genome Atlas database) and COVID-19 targets (collected from disease database of Genecards, OMIM, and NCBI). The correlations of NSCLC/COVID-19 targets and survival rates in patients with NSCLC were analyzed using the survival R package. Prognostic analyses were performed using univariate and multivariate Cox proportional hazards regression models. Furthermore, the targets in IS treatment of NSCLC/COVID-19 were defined as the overlapping targets of IS (predicted from drug database of TMSCP, HERBs, SwissTarget Prediction) and NSCLC/COVID-19 targets. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analysis of these treatment targets were performed aiming to understand the biological process, cellular component, molecular function and signaling pathway. The hub targets were analyzed by a protein–protein interaction network and the binding capacity with IS was characterized by molecular docking.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The hub targets for IS in the treatment of NSCLC/COVID-19 includes F2, SELE, MMP1, MMP2, AGTR1 and AGTR2, and the molecular docking results showed that the above target proteins had a good binding degree to IS. Network pharmacology showed that IS might affect the leucocytes migration, inflammation response and active oxygen species metabolic process, as well as regulate the interleukin-17, tumor necrosus factor and hypoxia-inducible factor-1 signaling pathway in NSCLC/COVID-19.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>IS may enhance the therapeutic efficacy of current clinical anti-inflammatory and anti-cancer therapy to benefit patients with NSCLC combined with COVID-19.</p>\u0000 </section>\u0000 </div>","PeriodicalId":56122,"journal":{"name":"Journal of Gene Medicine","volume":"26 7","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141536111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RNA expression profiling in lymphoblastoid cell lines from mutated and non-mutated amyotrophic lateral sclerosis patients 突变和非突变肌萎缩侧索硬化症患者淋巴母细胞系的 RNA 表达谱分析。
IF 3.2 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Pub Date : 2024-07-05 DOI: 10.1002/jgm.3711
Jessica Garau, Maria Garofalo, Francesca Dragoni, Eveljn Scarian, Rosalinda Di Gerlando, Luca Diamanti, Susanna Zucca, Matteo Bordoni, Orietta Pansarasa, Stella Gagliardi

Background

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the death of upper and lower motor neurons with an unknown etiology. The difficulty of recovering biological material from patients led to employ lymphoblastoid cell lines (LCLs) as a model for ALS because many pathways, typically located in neurons, are also activated in these cells.

Methods

To investigate the expression of coding and long non-coding RNAs in LCLs, a transcriptomic profiling of sporadic ALS (SALS) and mutated patients (FUS, TARDBP, C9ORF72 and SOD1) and matched controls was realized. Thus, differentially expressed genes (DEGs) were investigated among the different subgroups of patients. Peripheral blood mononuclear cells (PBMCs) were isolated and immortalized into LCLs via Epstein–Barr virus infection; RNA was extracted, and RNA-sequencing analysis was performed.

Results

Gene expression profiles of LCLs were genetic-background-specific; indeed, only 12 genes were commonly deregulated in all groups. Nonetheless, pathways enriched by DEGs in each group were also compared, and a total of 89 Kyoto Encyclopedia of Genes and Genomes (KEGG) terms were shared among all patients. Eventually, the similarity of affected pathways was also assessed when our data were matched with a transcriptomic profile realized in the PBMCs of the same patients.

Conclusions

We conclude that LCLs are a good model for the study of RNA deregulation in ALS.

背景:肌萎缩性脊髓侧索硬化症(ALS)是一种以上下运动神经元死亡为特征的神经退行性疾病,病因不明。由于很难从患者身上获取生物材料,因此淋巴母细胞系(LCL)被用作 ALS 的模型,因为这些细胞中也激活了许多通常位于神经元中的通路:为了研究编码RNA和长非编码RNA在LCLs中的表达,我们对散发性ALS(SALS)和突变患者(FUS、TARDBP、C9ORF72和SOD1)以及匹配的对照组进行了转录组学分析。因此,对不同亚组患者的差异表达基因(DEGs)进行了研究。通过 Epstein-Barr 病毒感染分离外周血单核细胞(PBMCs)并将其永生化为 LCLs;提取 RNA 并进行 RNA 序列分析:结果:LCLs的基因表达谱具有遗传背景特异性;事实上,只有12个基因在所有组别中普遍失调。然而,我们还比较了各组中 DEGs 丰富的通路,所有患者共有 89 个《京都基因与基因组百科全书》(KEGG)术语。最后,当我们的数据与同一患者的 PBMCs 中实现的转录组图谱相匹配时,受影响通路的相似性也得到了评估:我们得出结论:LCLs 是研究 ALS 中 RNA 失调的良好模型。
{"title":"RNA expression profiling in lymphoblastoid cell lines from mutated and non-mutated amyotrophic lateral sclerosis patients","authors":"Jessica Garau,&nbsp;Maria Garofalo,&nbsp;Francesca Dragoni,&nbsp;Eveljn Scarian,&nbsp;Rosalinda Di Gerlando,&nbsp;Luca Diamanti,&nbsp;Susanna Zucca,&nbsp;Matteo Bordoni,&nbsp;Orietta Pansarasa,&nbsp;Stella Gagliardi","doi":"10.1002/jgm.3711","DOIUrl":"10.1002/jgm.3711","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the death of upper and lower motor neurons with an unknown etiology. The difficulty of recovering biological material from patients led to employ lymphoblastoid cell lines (LCLs) as a model for ALS because many pathways, typically located in neurons, are also activated in these cells.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>To investigate the expression of coding and long non-coding RNAs in LCLs, a transcriptomic profiling of sporadic ALS (SALS) and mutated patients (<i>FUS</i>, <i>TARDBP</i>, <i>C9ORF72</i> and <i>SOD1</i>) and matched controls was realized. Thus, differentially expressed genes (DEGs) were investigated among the different subgroups of patients. Peripheral blood mononuclear cells (PBMCs) were isolated and immortalized into LCLs via Epstein–Barr virus infection; RNA was extracted, and RNA-sequencing analysis was performed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Gene expression profiles of LCLs were genetic-background-specific; indeed, only 12 genes were commonly deregulated in all groups. Nonetheless, pathways enriched by DEGs in each group were also compared, and a total of 89 Kyoto Encyclopedia of Genes and Genomes (KEGG) terms were shared among all patients. Eventually, the similarity of affected pathways was also assessed when our data were matched with a transcriptomic profile realized in the PBMCs of the same patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>We conclude that LCLs are a good model for the study of RNA deregulation in ALS.</p>\u0000 </section>\u0000 </div>","PeriodicalId":56122,"journal":{"name":"Journal of Gene Medicine","volume":"26 7","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jgm.3711","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141536112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Single-cell analysis of Crohn's disease: Unveiling heterogeneity and evaluating ustekinumab outcomes 克罗恩病的单细胞分析:揭示异质性并评估乌司替尼的疗效。
IF 3.2 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Pub Date : 2024-07-04 DOI: 10.1002/jgm.3715
Zheng-Yang Li, Yong-Hong Sun,  Qian-Hua, Hai-Yan Wang, Ya-Jie Wang,  Miao-Jiang

Background

The present study aimed to dissect the cellular complexity of Crohn's disease (CD) using single-cell RNA sequencing, focusing on identifying key cell populations and their transcriptional profiles in inflamed tissue.

Methods

We applied scRNA-sequencing to compare the cellular composition of CD patients with healthy controls, utilizing Seurat for clustering and annotation. Differential gene expression analysis and protein–protein interaction networks were constructed to identify crucial genes and pathways.

Results

Our study identified eight distinct cell types in CD, highlighting crucial fibroblast and T cell interactions. The analysis revealed key cellular communications and identified significant genes and pathways involved in the disease's pathology. The role of fibroblasts was underscored by elevated expression in diseased samples, offering insights into disease mechanisms and potential therapeutic targets, including responses to ustekinumab treatment, thus enriching our understanding of CD at a molecular level.

Conclusions

Our findings highlight the complex cellular and molecular interplay in CD, suggesting new biomarkers and therapeutic targets, offering insights into disease mechanisms and treatment implications.

背景:本研究旨在利用单细胞RNA测序技术剖析克罗恩病(CD)的细胞复杂性,重点是确定炎症组织中的关键细胞群及其转录特征:我们采用scRNA测序技术比较了CD患者和健康对照组的细胞组成,并利用Seurat进行了聚类和注释。结果:我们的研究在 CD 患者和健康对照组中发现了八种不同的细胞类型:结果:我们的研究确定了 CD 中八种不同的细胞类型,突出了成纤维细胞和 T 细胞之间的重要相互作用。分析揭示了关键的细胞通讯,并确定了参与疾病病理的重要基因和通路。成纤维细胞在患病样本中的表达升高凸显了成纤维细胞的作用,为疾病机制和潜在治疗靶点(包括对乌司替尼治疗的反应)提供了见解,从而丰富了我们对CD在分子水平上的认识:我们的研究结果突显了CD中复杂的细胞和分子相互作用,提出了新的生物标记物和治疗靶点,为疾病机制和治疗意义提供了新的视角。
{"title":"Single-cell analysis of Crohn's disease: Unveiling heterogeneity and evaluating ustekinumab outcomes","authors":"Zheng-Yang Li,&nbsp;Yong-Hong Sun,&nbsp; Qian-Hua,&nbsp;Hai-Yan Wang,&nbsp;Ya-Jie Wang,&nbsp; Miao-Jiang","doi":"10.1002/jgm.3715","DOIUrl":"10.1002/jgm.3715","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The present study aimed to dissect the cellular complexity of Crohn's disease (CD) using single-cell RNA sequencing, focusing on identifying key cell populations and their transcriptional profiles in inflamed tissue.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We applied scRNA-sequencing to compare the cellular composition of CD patients with healthy controls, utilizing Seurat for clustering and annotation. Differential gene expression analysis and protein–protein interaction networks were constructed to identify crucial genes and pathways.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Our study identified eight distinct cell types in CD, highlighting crucial fibroblast and T cell interactions. The analysis revealed key cellular communications and identified significant genes and pathways involved in the disease's pathology. The role of fibroblasts was underscored by elevated expression in diseased samples, offering insights into disease mechanisms and potential therapeutic targets, including responses to ustekinumab treatment, thus enriching our understanding of CD at a molecular level.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Our findings highlight the complex cellular and molecular interplay in CD, suggesting new biomarkers and therapeutic targets, offering insights into disease mechanisms and treatment implications.</p>\u0000 </section>\u0000 </div>","PeriodicalId":56122,"journal":{"name":"Journal of Gene Medicine","volume":"26 7","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jgm.3715","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141499763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biocompatible hydroxyapatite-based nano vehicle bypasses viral transduction and enables sustained silencing of a pluripotency marker gene, demonstrating desired differentiation in mouse embryonic stem cells 以羟基磷灰石为基础的生物相容性纳米载体绕过了病毒转导,实现了多能性标记基因的持续沉默,证明了小鼠胚胎干细胞的理想分化。
IF 3.2 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Pub Date : 2024-07-04 DOI: 10.1002/jgm.3716
Pranjita Zantye, Asha Dahiya, Meenal Kowshik, Sutapa Roy Ramanan, Indrani Talukdar

Background

Differentiation of pluripotent stem cells into desired lineages is the key aspect of regenerative medicine and cell-based therapy. Although RNA interference (RNAi) technology is exploited extensively for this, methods for long term silencing of the target genes leading to differentiation remain a challenge. Sustained knockdown of the target gene by RNAi is often inefficient as a result of low delivery efficiencies, protocol induced toxicity and safety concerns related to viral vectors. Earlier, we established octa-arginine functionalized hydroxyapatite nano vehicles (R8HNPs) for delivery of small interfering RNA (siRNA) against a pluripotency marker gene in mouse embryonic stem cells. Although we demonstrated excellent knockdown efficiency of the target gene, sustained gene silencing leading to differentiation was yet to be achieved.

Methods

To establish a sustained non-viral gene silencing protocol using R8HNP, we investigated various methods of siRNA delivery: double delivery of adherent cells (Adh-D), suspension delivery followed by adherent delivery (Susp + Adh), single delivery in suspension (Susp-S) and multiple deliveries in suspension (Susp-R). Sustained knockdown of a pluripotent marker gene followed by differentiation was analysed by reverse transcriptase-PCR, fluoresence-activated cell sorting and immunofluorescence techniques. Impact on cell viability as a result of repeated exposure of the R8HNP was also tested.

Results

Amongst the protocols tested, the most efficient knockdown of the target gene for a prolonged period of time was obtained by repeated suspension delivery of the R8HNP-siRNA conjugate. The long-term silencing of a pluripotency marker gene resulted in differentiation of R1 ESCs predominantly towards the extra embryonic and ectodermal lineages. Cells displayed excellent tolerance to repeated exposures of R8HNPs.

Conclusions

The results demonstrate that R8HNPs are promising, biocompatible, non-viral alternatives for prolonged gene silencing and obtaining differentiated cells for therapeutics.

背景:将多能干细胞分化成所需的细胞系是再生医学和细胞疗法的关键环节。虽然 RNA 干扰(RNAi)技术在这方面得到了广泛应用,但长期沉默导致分化的靶基因的方法仍然是一个挑战。用 RNAi 技术持续敲除靶基因的效率往往不高,原因包括传递效率低、方案诱导毒性以及与病毒载体相关的安全问题。早些时候,我们建立了八精氨酸功能化羟基磷灰石纳米载体(R8HNPs),用于在小鼠胚胎干细胞中递送针对多能性标记基因的小干扰 RNA(siRNA)。虽然我们证明了目标基因的极佳敲除效率,但尚未实现导致分化的持续基因沉默:为了利用 R8HNP 建立一种持续的非病毒基因沉默方案,我们研究了多种 siRNA 递送方法:粘附细胞双递送(Adh-D)、悬浮递送后粘附递送(Susp + Adh)、悬浮液中单次递送(Susp-S)和悬浮液中多次递送(Susp-R)。通过反转录酶-PCR、荧光激活细胞分选和免疫荧光技术分析了多能标记基因持续敲除后的分化情况。此外,还测试了重复暴露 R8HNP 对细胞活力的影响:结果:在测试的各种方案中,重复悬浮递送 R8HNP-siRNA 共轭物能最有效地长期敲除目标基因。长期沉默多能性标记基因导致 R1 ESCs 主要向胚外和外胚层系分化。细胞对反复暴露于 R8HNPs 表现出极好的耐受性:研究结果表明,R8HNPs 是一种前景广阔、生物相容性好的非病毒替代品,可用于长期基因沉默和获得用于治疗的分化细胞。
{"title":"Biocompatible hydroxyapatite-based nano vehicle bypasses viral transduction and enables sustained silencing of a pluripotency marker gene, demonstrating desired differentiation in mouse embryonic stem cells","authors":"Pranjita Zantye,&nbsp;Asha Dahiya,&nbsp;Meenal Kowshik,&nbsp;Sutapa Roy Ramanan,&nbsp;Indrani Talukdar","doi":"10.1002/jgm.3716","DOIUrl":"10.1002/jgm.3716","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Differentiation of pluripotent stem cells into desired lineages is the key aspect of regenerative medicine and cell-based therapy. Although RNA interference (RNAi) technology is exploited extensively for this, methods for long term silencing of the target genes leading to differentiation remain a challenge. Sustained knockdown of the target gene by RNAi is often inefficient as a result of low delivery efficiencies, protocol induced toxicity and safety concerns related to viral vectors. Earlier, we established octa-arginine functionalized hydroxyapatite nano vehicles (R8HNPs) for delivery of small interfering RNA (siRNA) against a pluripotency marker gene in mouse embryonic stem cells. Although we demonstrated excellent knockdown efficiency of the target gene, sustained gene silencing leading to differentiation was yet to be achieved.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>To establish a sustained non-viral gene silencing protocol using R8HNP, we investigated various methods of siRNA delivery: double delivery of adherent cells (Adh-D), suspension delivery followed by adherent delivery (Susp + Adh), single delivery in suspension (Susp-S) and multiple deliveries in suspension (Susp-R). Sustained knockdown of a pluripotent marker gene followed by differentiation was analysed by reverse transcriptase-PCR, fluoresence-activated cell sorting and immunofluorescence techniques. Impact on cell viability as a result of repeated exposure of the R8HNP was also tested.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Amongst the protocols tested, the most efficient knockdown of the target gene for a prolonged period of time was obtained by repeated suspension delivery of the R8HNP-siRNA conjugate. The long-term silencing of a pluripotency marker gene resulted in differentiation of R1 ESCs predominantly towards the extra embryonic and ectodermal lineages. Cells displayed excellent tolerance to repeated exposures of R8HNPs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The results demonstrate that R8HNPs are promising, biocompatible, non-viral alternatives for prolonged gene silencing and obtaining differentiated cells for therapeutics.</p>\u0000 </section>\u0000 </div>","PeriodicalId":56122,"journal":{"name":"Journal of Gene Medicine","volume":"26 7","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jgm.3716","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141499762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Decoding dysregulated genes, molecular pathways and microRNAs involved in cervical cancer 解码宫颈癌相关的失调基因、分子通路和 microRNA。
IF 3.2 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Pub Date : 2024-07-01 DOI: 10.1002/jgm.3713
Manoj Khokhar, Purnima Kartha, Sana Hassan, Rajan Kumar Pandey

Background

The present study aimed to identify dysregulated genes, molecular pathways, and regulatory mechanisms in human papillomavirus (HPV)-associated cervical cancers. We have investigated the disease-associated genes along with the Gene Ontology, survival prognosis, transcription factors and the microRNA (miRNA) that are involved in cervical carcinogenesis, enabling a deeper comprehension of cervical cancer linked to HPV.

Methods

We used 10 publicly accessible Gene Expression Omnibus (GEO) datasets to examine the patterns of gene expression in cervical cancer. Differentially expressed genes (DEGs), which showed a clear distinction between cervical cancer and healthy tissue samples, were analyzed using the GEO2R tool. Additional bioinformatic techniques were used to carry out pathway analysis and functional enrichment, as well as to analyze the connection between altered gene expression and HPV infection.

Results

In total, 48 DEGs were identified to be differentially expressed in cervical cancer tissues in comparison to healthy tissues. Among DEGs, CCND1, CCNA2 and SPP1 were the key dysregulated genes involved in HPV-associated cervical cancer. The five common miRNAs that were identified against these genes are miR-7-5p, miR-16-5p, miR-124-3p, miR-10b-5p and miR-27a-3p. The hub-DEGs targeted by miRNA hsa-miR-27a-3p are controlled by the common transcription factor SP1.

Conclusions

The present study has identified DEGs involved in HPV-associated cervical cancer progression and the various molecular pathways and transcription factors regulating them. These findings have led to a better understanding of cervical cancer resulting in the development and identification of possible therapeutic and intervention targets, respectively.

研究背景本研究旨在确定人乳头瘤病毒(HPV)相关宫颈癌中的失调基因、分子通路和调控机制。我们对疾病相关基因以及基因本体、生存预后、转录因子和参与宫颈癌发生的微RNA(miRNA)进行了研究,从而更深入地了解与HPV相关的宫颈癌:我们使用了 10 个可公开访问的基因表达总库(GEO)数据集来研究宫颈癌的基因表达模式。我们使用 GEO2R 工具分析了宫颈癌与健康组织样本之间有明显区别的差异表达基因(DEGs)。此外,还利用生物信息学技术进行了通路分析和功能富集,并分析了基因表达改变与 HPV 感染之间的联系:结果:与健康组织相比,宫颈癌组织中共有 48 个 DEGs 存在差异表达。在 DEGs 中,CCND1、CCNA2 和 SPP1 是 HPV 相关宫颈癌的关键失调基因。针对这些基因的五种常见 miRNA 包括 miR-7-5p、miR-16-5p、miR-124-3p、miR-10b-5p 和 miR-27a-3p。miRNA hsa-miR-27a-3p 靶向的枢纽-DEGs 受共同转录因子 SP1 的控制:本研究发现了参与 HPV 相关宫颈癌进展的 DEGs,以及调控这些 DEGs 的各种分子通路和转录因子。这些发现使人们对宫颈癌有了更深入的了解,从而分别开发和确定了可能的治疗和干预靶点。
{"title":"Decoding dysregulated genes, molecular pathways and microRNAs involved in cervical cancer","authors":"Manoj Khokhar,&nbsp;Purnima Kartha,&nbsp;Sana Hassan,&nbsp;Rajan Kumar Pandey","doi":"10.1002/jgm.3713","DOIUrl":"10.1002/jgm.3713","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The present study aimed to identify dysregulated genes, molecular pathways, and regulatory mechanisms in human papillomavirus (HPV)-associated cervical cancers. We have investigated the disease-associated genes along with the Gene Ontology, survival prognosis, transcription factors and the microRNA (miRNA) that are involved in cervical carcinogenesis, enabling a deeper comprehension of cervical cancer linked to HPV.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We used 10 publicly accessible Gene Expression Omnibus (GEO) datasets to examine the patterns of gene expression in cervical cancer. Differentially expressed genes (DEGs), which showed a clear distinction between cervical cancer and healthy tissue samples, were analyzed using the GEO2R tool. Additional bioinformatic techniques were used to carry out pathway analysis and functional enrichment, as well as to analyze the connection between altered gene expression and HPV infection.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In total, 48 DEGs were identified to be differentially expressed in cervical cancer tissues in comparison to healthy tissues. Among DEGs, CCND1, CCNA2 and SPP1 were the key dysregulated genes involved in HPV-associated cervical cancer. The five common miRNAs that were identified against these genes are miR-7-5p, miR-16-5p, miR-124-3p, miR-10b-5p and miR-27a-3p. The hub-DEGs targeted by miRNA hsa-miR-27a-3p are controlled by the common transcription factor SP1.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The present study has identified DEGs involved in HPV-associated cervical cancer progression and the various molecular pathways and transcription factors regulating them. These findings have led to a better understanding of cervical cancer resulting in the development and identification of possible therapeutic and intervention targets, respectively.</p>\u0000 </section>\u0000 </div>","PeriodicalId":56122,"journal":{"name":"Journal of Gene Medicine","volume":"26 7","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jgm.3713","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141473022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Gene Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1